Kritika Subramanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kritika Subramanian has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Joseph R. Osborne
Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, USA
5 shared publications- Gary Brandeis
Department of Medicine Icahn School of Medicine at Mount Sinai New York New York USA
3 shared publications - Himanshu Nagar
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
3 shared publications - Johan Van Weyenbergh
KU Leuven
3 shared publications - Joseph R. Osborne
Department of Radiology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY
3 shared publications Juana Martinez
Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, USA
3 shared publications
Latest Publications
- Open Access
Reasons for Discordance between 68Ga-PSMA-PET and Magnetic Resonance Imaging in Men with Metastatic Prostate Cancer
Background: PSMA PET has emerged as a “gold standard” imaging modality for assessing prostate cancer metastases. However, it is not universally available, and this limits its impact. In contrast, whole-body MRI is much more widely available but misses more lesions. This study aims to improve the interpretation of whole-body MRI by comparing false negative scans retrospectively to PSMA PET. Methods: This study was a retrospective sub-analysis of a prospectively collected database of patients who participated in a clinical trial of PSMA PET/MRI comparing PSMA PET and whole-body MRI from 2018–2021. Subjects whose separately read PSMA PET and MRI diagnostic reports showed discrepancies (“false negative” MRI cases) were selected for sub-analysis. The cases were reviewed by the same attending radiologist who originally read the scans. The radiologist noted specific features on MRI indicating metastatic disease that were initially missed. Results: Of 263 cases, 38 (14%) met the inclusion criteria and were reviewed. Six classes of mpMRI false negatives were identified: anatomically normal (18, 47%), atypical MRI appearance (6, 16%), mischaracterization (1, 3%), undercall (6, 16%), obscured (4, 11%), and no abnormality on MRI (3, 8%). Considering that the atypical and undercalled cases could have been adjusted in retrospect, and that 4 additional cases had positive lesions to the same extent and 11 further cases had disease confined to the pelvis, only 11 (4%) of the original 263 would have had disease outside of a conventional radiation treatment plan. Conclusion: Notably, almost 50% of the cases, including most lymph node metastases, were anatomically normal using standard criteria. This suggests that current anatomic criteria for evaluating prostate cancer lymph node metastases are not ideal, and there is a need for improved criteria. In addition, 32% of cases involved some element of human interpretive error, and, therefore, improving reader training may lead to more accurate results.
Open AccessReasons for Discordance between 68Ga-PSMA-PET and Magnetic Resonance Imaging in Men with Metastatic Prostate Cancer
Background: PSMA PET has emerged as a “gold standard” imaging modality for assessing prostate cancer metastases. However, it is not universally available, and this limits its impact. In contrast, whole-body MRI is much more widely available but misses more lesions. This study aims to improve the interpretation of whole-body MRI by comparing false negative scans retrospectively to PSMA PET. Methods: This study was a retrospective sub-analysis of a prospectively collected database of patients who participated in a clinical trial of PSMA PET/MRI comparing PSMA PET and whole-body MRI from 2018–2021. Subjects whose separately read PSMA PET and MRI diagnostic reports showed discrepancies (“false negative” MRI cases) were selected for sub-analysis. The cases were reviewed by the same attending radiologist who originally read the scans. The radiologist noted specific features on MRI indicating metastatic disease that were initially missed. Results: Of 263 cases, 38 (14%) met the inclusion criteria and were reviewed. Six classes of mpMRI false negatives were identified: anatomically normal (18, 47%), atypical MRI appearance (6, 16%), mischaracterization (1, 3%), undercall (6, 16%), obscured (4, 11%), and no abnormality on MRI (3, 8%). Considering that the atypical and undercalled cases could have been adjusted in retrospect, and that 4 additional cases had positive lesions to the same extent and 11 further cases had disease confined to the pelvis, only 11 (4%) of the original 263 would have had disease outside of a conventional radiation treatment plan. Conclusion: Notably, almost 50% of the cases, including most lymph node metastases, were anatomically normal using standard criteria. This suggests that current anatomic criteria for evaluating prostate cancer lymph node metastases are not ideal, and there is a need for improved criteria. In addition, 32% of cases involved some element of human interpretive error, and, therefore, improving reader training may lead to more accurate results.
- 1 November 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (6) , e230166
Alternate CMS Payment Structure for Outpatient Services: A Road to Improving Access to Molecular Imaging in Oncologic Care
- 1 November 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (6) , e230166
Alternate CMS Payment Structure for Outpatient Services: A Road to Improving Access to Molecular Imaging in Oncologic Care
- 4 August 2023
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (12) , 3509-3510
PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary
- 4 August 2023
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (12) , 3509-3510
PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary
- 12 July 2023
- Published by Wiley in Clinical Physiology and Functional Imaging
- Vol. 44 (1) , 44-48
Lobar quantification of pulmonary perfusion prior to minimally invasive lung reduction improves prediction of postprocedure outcomes: A pilot study
Background: Endobronchial valve placement is a minimally invasive option for treatment of patients with severe emphysema, by reducing lung volumes in lobes with both poor ventilation and perfusion; ventilation is determined by emphysematous scores and perfusion by quantitative lung perfusion imaging. CT‐based fissure identifying artificial intelligence algorithms have recently demonstrated enhanced quantification of the perfusion in a 5‐lobar analysis. We hypothesized that this newly developed algorithm may offer greater utility in determining target treatment lobes by supplementing the radiographic risk stratification initiated by the conventional emphysematous scores alone.Methods: Quantification images of 43 deidentified individuals underwent perfusion SPECT/CT with Tc99m Macro‐Aggregated Albumin (4mCi/148MBq intravenous) using both conventional zonal anatomy and AI augmented 5‐lobar analysis.Analysis: Images were reviewed to demonstrate that the new algorithm was not inferior to standard of care imaging with zonal segmentation. A pilot subcohort analysis of 4 patients with severe emphysema who had pre‐endobronchial valve placement imaging demonstrated that an emphysema‐perfusion ratio greater than 3 was indicative of a potential target lobe.Discussion: We conclude that 5‐lobar analysis in not inferior to conventional zonal analysis and allows the determination of emphysema‐to‐perfusion ratio. Preliminary review of a small subcohort suggests an emphysema‐to‐perfusion ratio greater than 3 for a lobe may clinically benefit in endobronchial valve placement. Further evaluation with prospective studies and larger sample sizes are recommended before clinical implementation.
- 12 July 2023
- Published by Wiley in Clinical Physiology and Functional Imaging
- Vol. 44 (1) , 44-48
Lobar quantification of pulmonary perfusion prior to minimally invasive lung reduction improves prediction of postprocedure outcomes: A pilot study
Background: Endobronchial valve placement is a minimally invasive option for treatment of patients with severe emphysema, by reducing lung volumes in lobes with both poor ventilation and perfusion; ventilation is determined by emphysematous scores and perfusion by quantitative lung perfusion imaging. CT‐based fissure identifying artificial intelligence algorithms have recently demonstrated enhanced quantification of the perfusion in a 5‐lobar analysis. We hypothesized that this newly developed algorithm may offer greater utility in determining target treatment lobes by supplementing the radiographic risk stratification initiated by the conventional emphysematous scores alone.Methods: Quantification images of 43 deidentified individuals underwent perfusion SPECT/CT with Tc99m Macro‐Aggregated Albumin (4mCi/148MBq intravenous) using both conventional zonal anatomy and AI augmented 5‐lobar analysis.Analysis: Images were reviewed to demonstrate that the new algorithm was not inferior to standard of care imaging with zonal segmentation. A pilot subcohort analysis of 4 patients with severe emphysema who had pre‐endobronchial valve placement imaging demonstrated that an emphysema‐perfusion ratio greater than 3 was indicative of a potential target lobe.Discussion: We conclude that 5‐lobar analysis in not inferior to conventional zonal analysis and allows the determination of emphysema‐to‐perfusion ratio. Preliminary review of a small subcohort suggests an emphysema‐to‐perfusion ratio greater than 3 for a lobe may clinically benefit in endobronchial valve placement. Further evaluation with prospective studies and larger sample sizes are recommended before clinical implementation.
- Open Access
- 23 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men
Prostate cancer (PC) staging with conventional imaging often includes multiparametric magnetic resonance (MR) of the prostate, computed tomography (CT) of the chest, abdomen, and pelvis, and whole-body bone scintigraphy. The recent development of highly sensitive and specific prostate specific membrane antigen (PSMA) positron emission tomography (PET) has suggested that prior imaging techniques may be insufficiently sensitive or specific, particularly when evaluating small pathologic lesions. As PSMA PET/CT is considered to be superior for multiple clinical indications, it is being deployed as the new multidisciplinary standard-of-care. Given this, we performed a cost-effectiveness analysis of [18F]DCFPyL PSMA PET/CT imaging in the evaluation of PC relative to conventional imaging and anti-3-[18F]FACBC (18F-Fluciclovine) PET/CT. We also conducted a single institution review of PSMA PET/CT scans performed primarily for research indications from January 2018 to October 2021. Our snapshot of this period of time in our catchment demonstrated that PSMA PET/CT imaging was disproportionately accessed by men of European ancestry (EA) and those residing in zip codes associated with a higher median household income. The cost-effectiveness analysis demonstrated that [18F]DCFPyL PET/CT should be considered as an alternative to anti-3-[18F]FACBC PET/CT and standard of care imaging for prostate cancer staging. [18F]DCFPyL PET/CT is a new imaging modality to evaluate PC patients with higher sensitivity and specificity in detecting disease than other prostate specific imaging studies. Despite this, access may be inequitable. This discrepancy will need to be addressed proactively as the distribution network of the radiotracer includes both academic and non-academic sites nationwide.
- 23 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Open AccessComplex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men
Prostate cancer (PC) staging with conventional imaging often includes multiparametric magnetic resonance (MR) of the prostate, computed tomography (CT) of the chest, abdomen, and pelvis, and whole-body bone scintigraphy. The recent development of highly sensitive and specific prostate specific membrane antigen (PSMA) positron emission tomography (PET) has suggested that prior imaging techniques may be insufficiently sensitive or specific, particularly when evaluating small pathologic lesions. As PSMA PET/CT is considered to be superior for multiple clinical indications, it is being deployed as the new multidisciplinary standard-of-care. Given this, we performed a cost-effectiveness analysis of [18F]DCFPyL PSMA PET/CT imaging in the evaluation of PC relative to conventional imaging and anti-3-[18F]FACBC (18F-Fluciclovine) PET/CT. We also conducted a single institution review of PSMA PET/CT scans performed primarily for research indications from January 2018 to October 2021. Our snapshot of this period of time in our catchment demonstrated that PSMA PET/CT imaging was disproportionately accessed by men of European ancestry (EA) and those residing in zip codes associated with a higher median household income. The cost-effectiveness analysis demonstrated that [18F]DCFPyL PET/CT should be considered as an alternative to anti-3-[18F]FACBC PET/CT and standard of care imaging for prostate cancer staging. [18F]DCFPyL PET/CT is a new imaging modality to evaluate PC patients with higher sensitivity and specificity in detecting disease than other prostate specific imaging studies. Despite this, access may be inequitable. This discrepancy will need to be addressed proactively as the distribution network of the radiotracer includes both academic and non-academic sites nationwide.
- Open Access
- 25 April 2023
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine Technology
- Vol. 51 (3) , 215-219
α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States
The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop 225Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent. Visual Abstract
- 25 April 2023
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine Technology
- Vol. 51 (3) , 215-219
Open Accessα-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States
The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop 225Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent. Visual Abstract
- 13 April 2023
- Published by Wiley in The Prostate
- Vol. 83 (10) , 901-911
Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literature
Background: Targeted radionuclide therapy with Actinium‐225‐labeled prostate‐specific membrane antigen agents (225Ac‐PSMA) is currently being studied in clinical trials for patients with metastatic castration‐resistant prostate cancer (mCRPC). Compared to β‐emitting therapeutic radionuclides, alpha‐emitters (e.g., 225Ac) have a significantly higher linear energy transfer and significantly shorter range. As a result, alpha emitters could be expected to improve efficacy and reduce bystander toxicity. This systematic literature review was conducted to evaluate the impact of sequencing of 177Lu‐PSMA and 225Ac‐PSMA targeted radionuclide therapy (TRT) in mCRPC.Methods: The present systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. The searches were made using relevant keywords in the PubMed, Scopus, and Web of Science databases, and articles up to August 22, 2022, were included. Publications were excluded if they were duplicate publications, wrong study or publication format, or discussing a topic out of scope. Data on efficacy, toxicity, and health‐related quality of life were extracted from the individual articles. The I2 index was used to measure the extent of heterogeneity amongst studies. In the studies that reported subgroup outcomes according to the prior status on 177Lu‐PSMA TRT, pooled estimates of the main outcomes were generated through descriptive analysis. Quality assessment was performed using the Newark−Ottawa‐scale.Results: The study included 12 articles; 1 series was performed prospectively. In total, data of 329 patients were analyzed. About 40.1% (n = 132) of the included men were pretreated with 177Lu‐PSMA TRT. Seven studies, including data of 212 individuals, were eligible for quantitative analysis based on reporting outcomes of the subgroups according to their prior status on 177Lu‐PSMA TRT. >25% PSA decline after 225Ac‐PSMA TRT was lower in individuals who received prior 177Lu‐PSMA TRT (pooled median 42.7%) compared to those who did not (pooled median 15.4%). The pooled medians of the reported median progression‐free survival and overall survival for pretreated versus not pretreated individuals was 4.3 versus 14.3 months and 11.1 versus 9.2 months, respectively. However, the outcomes for each individual study were reported inconsistently (I2 = 99.9%). None of the included studies stratified the report of adverse events or changes in health‐related quality of life for the subgroups.Conclusions: 225Ac‐PSMA TRT is an experimental treatment for men with mCRPC. There is limited data available from high‐quality trials but so far PSMA‐targeted TRT has demonstrated a low morbidity profile. Our review revealed that there is a possible decrease in efficacy of targeted alpha‐particle therapy if individuals previously were exposed to 177Lu‐PSMA TRT. However, the level of evidence is low. The underlying mechanism by which 177Lu‐PSMA TRT might trigger possible radioresistance as well as randomized controlled trials are required to establish the therapeutic efficacy and safety of 225‐Ac‐PSMA TRT in men refractory to 177Lu‐PSMA TRT.
- 13 April 2023
- Published by Wiley in The Prostate
- Vol. 83 (10) , 901-911
Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literature
Background: Targeted radionuclide therapy with Actinium‐225‐labeled prostate‐specific membrane antigen agents (225Ac‐PSMA) is currently being studied in clinical trials for patients with metastatic castration‐resistant prostate cancer (mCRPC). Compared to β‐emitting therapeutic radionuclides, alpha‐emitters (e.g., 225Ac) have a significantly higher linear energy transfer and significantly shorter range. As a result, alpha emitters could be expected to improve efficacy and reduce bystander toxicity. This systematic literature review was conducted to evaluate the impact of sequencing of 177Lu‐PSMA and 225Ac‐PSMA targeted radionuclide therapy (TRT) in mCRPC.Methods: The present systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. The searches were made using relevant keywords in the PubMed, Scopus, and Web of Science databases, and articles up to August 22, 2022, were included. Publications were excluded if they were duplicate publications, wrong study or publication format, or discussing a topic out of scope. Data on efficacy, toxicity, and health‐related quality of life were extracted from the individual articles. The I2 index was used to measure the extent of heterogeneity amongst studies. In the studies that reported subgroup outcomes according to the prior status on 177Lu‐PSMA TRT, pooled estimates of the main outcomes were generated through descriptive analysis. Quality assessment was performed using the Newark−Ottawa‐scale.Results: The study included 12 articles; 1 series was performed prospectively. In total, data of 329 patients were analyzed. About 40.1% (n = 132) of the included men were pretreated with 177Lu‐PSMA TRT. Seven studies, including data of 212 individuals, were eligible for quantitative analysis based on reporting outcomes of the subgroups according to their prior status on 177Lu‐PSMA TRT. >25% PSA decline after 225Ac‐PSMA TRT was lower in individuals who received prior 177Lu‐PSMA TRT (pooled median 42.7%) compared to those who did not (pooled median 15.4%). The pooled medians of the reported median progression‐free survival and overall survival for pretreated versus not pretreated individuals was 4.3 versus 14.3 months and 11.1 versus 9.2 months, respectively. However, the outcomes for each individual study were reported inconsistently (I2 = 99.9%). None of the included studies stratified the report of adverse events or changes in health‐related quality of life for the subgroups.Conclusions: 225Ac‐PSMA TRT is an experimental treatment for men with mCRPC. There is limited data available from high‐quality trials but so far PSMA‐targeted TRT has demonstrated a low morbidity profile. Our review revealed that there is a possible decrease in efficacy of targeted alpha‐particle therapy if individuals previously were exposed to 177Lu‐PSMA TRT. However, the level of evidence is low. The underlying mechanism by which 177Lu‐PSMA TRT might trigger possible radioresistance as well as randomized controlled trials are required to establish the therapeutic efficacy and safety of 225‐Ac‐PSMA TRT in men refractory to 177Lu‐PSMA TRT.
- Open Access
- 24 December 2022
- Published by Elsevier in Translational Oncology
- Vol. 28, 101593
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
- 24 December 2022
- Published by Elsevier in Translational Oncology
- Vol. 28, 101593
Open AccessCyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
- 2 December 2022
- Published by Elsevier in Clinical Imaging
- Vol. 94, 50-55
Access to cardiac PET/CT by sarcoidosis patients and cost-effectiveness analysis of cardiac PET/MR compared to the standard of care
- 2 December 2022
- Published by Elsevier in Clinical Imaging
- Vol. 94, 50-55
Access to cardiac PET/CT by sarcoidosis patients and cost-effectiveness analysis of cardiac PET/MR compared to the standard of care
- 28 February 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 49, 677
Parenteral nutrition in SARS-CoV-2 patients on non-invasive ventilation: A reply - Letter to the editor
- 28 February 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 49, 677
Parenteral nutrition in SARS-CoV-2 patients on non-invasive ventilation: A reply - Letter to the editor